|
시장보고서
상품코드
1625468
난치성 통풍 시장 규모, 점유율, 동향, 산업 분석 보고서 : 치료 유형별, 유통 채널별, 지역별 - 시장 예측(2025-2034년)Refractory Gout Market Size, Share, Trends, Industry Analysis Report: By Treatment Type, Distribution Channel, and Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최신 조사에 따르면, 전 세계 난치성 통풍 시장 규모는 2034년까지 15억 9,924만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 상세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.
난치성 통풍 시장은 기존 치료법에 반응하지 않는 중증 통풍 환자의 증가로 인해 꾸준히 성장하고 있습니다. 난치성 통풍은 표준 치료에도 불구하고 증상이 지속되는 것이 특징이며, 고도의 치료적 접근이 필요하여 시장 성장에 크게 기여하고 있습니다. 시장은 생물학적 치료와 비생물학적 치료로 구분되며, 생물학적 치료는 표적 작용과 복잡한 환자 관리에서 높은 효과로 인해 주목할 만한 시장 점유율을 차지하고 있습니다. 단클론항체 및 효소 억제제를 포함한 이러한 치료법은 점점 더 많은 지지를 받고 있으며, 이는 시장 수요를 증가시키고 시장 확대를 촉진하고 있습니다.
혁신적인 치료 옵션의 가용성에 대한 의료 전문가와 환자의 인식이 높아지는 것도 시장 규모를 확대하는 중요한 요인입니다. 난치성 통풍의 주요 치료 기관인 병원과 전문 클리닉은 고급 치료와 전문 치료를 받을 수 있기 때문에 시장 성장에 매우 중요한 역할을 하고 있습니다. 이 분야는 생물학적 제제의 채택 증가와 전문 시설의 가용성에 힘입어 큰 성장이 예상됩니다.
기술 발전, 지속적인 연구 개발 및 신약 승인은 난치성 통풍 시장을 더욱 강화시키고 있습니다. 또한, 중증 통풍에 취약한 노인 인구의 증가는 시장 수요 증가에 기여하고 있습니다. 첨단 치료법에 대한 접근성을 개선하기 위한 정부의 적극적인 노력과 의료 정책도 시장 확대를 뒷받침하고 있습니다.
난치성 통풍 시장 보고서 하이라이트
치료 유형별로는 생물학적 제제가 광범위한 적용 범위와 증상 관리 효과로 난치성 통풍 시장에서 큰 시장 점유율을 차지하고 있습니다.
유통 채널별로 보면 중증 및 복합적인 환자를 치료할 수 있는 병원 및 전문 클리닉이 예측 기간 동안 큰 성장을 이룰 것으로 예상됩니다.
북미는 고도의 의료 인프라를 갖추고 통풍 유병률이 높아 난치성 통풍 시장에서 가장 큰 점유율을 차지하고 있습니다.
아시아태평양은 신흥국의 헬스케어 투자 증가와 통풍 관리에 대한 인식이 높아짐에 따라 예측 기간 동안 큰 성장을 보일 것으로 예상됩니다.
목차
제1장 소개
제2장 주요 요약
제3장 조사 방법
제4장 세계의 난치성 통풍 시장 인사이트
- 시장 현황
- 난치성 통풍 시장 역학
- 성장 촉진요인과 기회
- 난치성 통풍 치료의 생물학적 제제 수요 증가
- 맞춤형 의료와 유전자 검사에 대한 주목이 높아진다
- 성장 억제요인과 과제
- 고액의 치료비
- 성장 촉진요인과 기회
- PESTEL 분석
- 난치성 통풍 시장 애플리케이션 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 세계의 난치성 통풍 시장 : 치료 유형별
- 주요 조사 결과
- 소개
- 생물학적 치료
- 비생물학적 치료
제6장 세계의 난치성 통풍 시장 : 유통 채널별
- 주요 조사 결과
- 소개
- 병원 및 전문 클리닉
- 소매 약국
- 온라인 약국
제7장 세계의 난치성 통풍 시장 : 지역별
- 주요 조사 결과
- 소개
- 난치성 통풍 시장 평가 : 지역, 2020-2034년
- 북미
- 북미 : 치료 유형별, 2020-2034년
- 북미 : 유통 채널별, 2020-2034년
- 미국
- 캐나다
- 유럽
- 유럽 : 치료 유형별, 2020-2034년
- 유럽 : 유통 채널별, 2020-2034년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 치료 유형별, 2020-2034년
- 아시아태평양 : 유통 채널별, 2020-2034년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 치료 유형별, 2020-2034년
- 중동 및 아프리카 : 유통 채널별, 2020-2034년
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 치료 유형별, 2020-2034년
- 라틴아메리카 : 유통 채널별, 2020-2034년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제8장 경쟁 구도
- 확대와 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제9장 기업 개요
- Horizon Therapeutics
- Novartis AG
- Takeda Pharmaceuticals
- Grifols, S.A.
- Ironwood Pharmaceuticals
- Selecta Biosciences
- Teijin Pharma
- Pfizer Inc.
- Sobi(Swedish Orphan Biovitrum)
- LG Chem
- AstraZeneca
- Mylan N.V.
- Sanofi
- GlaxoSmithKline plc(GSK)
- Ardea Biosciences
The global refractory gout market size is expected to reach USD 1,599.24 million by 2034, according to a new study by Polaris Market Research. The report "Refractory Gout Market Size, Share, Trends, Industry Analysis Report: By Treatment Type (Biological and Non-Biological Treatments), Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The refractory gout market is witnessing steady expansion, driven by the increasing prevalence of severe gout cases unresponsive to conventional therapies. Refractory gout, characterized by persistent symptoms despite standard treatment, requires advanced therapeutic approaches, which significantly contribute to market growth. The market is segmented into biological and non-biological treatments, with biological therapies gaining notable market share due to their targeted action and higher efficacy in managing complex cases. These treatments, which include monoclonal antibodies and enzyme inhibitors, are increasingly favored, boosting market demand and fostering market expansion.
The rising awareness among healthcare professionals and patients about the availability of innovative treatment options is another crucial factor driving market size. Hospitals and specialty clinics, as primary treatment providers for refractory gout, play a pivotal role in market growth by offering access to advanced therapies and expert care. This segment is expected to witness significant growth, supported by the increasing adoption of biologics and the availability of specialized facilities.
Technological advancements, ongoing research and development, and the approval of novel drugs are further enhancing the refractory gout market. Additionally, the growing geriatric population, which is more susceptible to severe gout, is contributing to the increasing market demand. Favorable government initiatives and healthcare policies aimed at improving access to advanced treatments also support market expansion.
Refractory Gout Market Report Highlights:
In terms of treatment type, the biological treatment segment holds the significant market share in the refractory gout market due to their broad application and efficacy in managing symptoms.
By distribution channel, the hospitals and specialty clinics segment is expected to witness significant growth over the forecast period, driven by their capacity to handle severe and complex cases.
North America holds the largest share of the refractory gout market, with its advanced healthcare infrastructure and high prevalence of gout.
Asia Pacific is expected to witness significant growth over the forecast period, owing to increasing healthcare investments and rising awareness of gout management in emerging economies.
Polaris Market Research has segmented the refractory gout market report on the basis of treatment type, distribution channel, and region:
By Treatment Type Outlook (Revenue USD Million, 2020-2034)
- Biologics
- Pegloticase (Krystexxa)
- Canakinumab
- Non-Biologics
- NSAIDs
- Corticosteroids
- Colchicine
- Uricosurics (e.g., probenecid)
By Distribution Channel Outlook (Revenue USD Million, 2020-2034)
- Hospitals and Specialty Clinics
- Retail Pharmacies
- Online Pharmacies
By Regional Outlook (Revenue USD Million, 2020-2034)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Refractory Gout Market Insights
- 4.1. Refractory Gout Market - Market Snapshot
- 4.2. Refractory Gout Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising Demand for Biologics in Refractory Gout Treatment
- 4.2.1.2. Surging Focus on Personalized Medicine and Genetic Testing
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High Treatment Costs
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Refractory Gout Market Application Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Refractory Gout Market, by Treatment Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 5.3. Biologics
- 5.3.1. Global Refractory Gout Market, by Biologics, by Region, 2020-2034 (USD Million)
- 5.3.2. Pegloticase (Krystexxa)
- 5.3.2.1. Global Refractory Gout Market, by Pegloticase (Krystexxa), by Region, 2020-2034 (USD Million)
- 5.3.3. Canakinumab
- 5.3.3.1. Global Refractory Gout Market, by Canakinumab, by Region, 2020-2034 (USD Million)
- 5.4. Non-Biologics
- 5.4.1. Global Refractory Gout Market, by Non-Biologics, by Region, 2020-2034 (USD Million)
- 5.4.2. NSAIDs
- 5.4.2.1. Global Refractory Gout Market, by NSAIDs, by Region, 2020-2034 (USD Million)
- 5.4.3. Corticosteroids
- 5.4.3.1. Global Refractory Gout Market, by Corticosteroids, by Region, 2020-2034 (USD Million)
- 5.4.4. Colchicine
- 5.4.4.1. Global Refractory Gout Market, by Colchicine, by Region, 2020-2034 (USD Million)
- 5.4.5. Uricosurics (e.g., probenecid)
- 5.4.5.1. Global Refractory Gout Market, by Uricosurics (e.g., probenecid), by Region, 2020-2034 (USD Million)
6. Global Refractory Gout Market, by Distribution Channel
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 6.3. Hospitals and Specialty Clinics
- 6.3.1. Global Refractory Gout Market, by Hospitals and Specialty Clinics, by Region, 2020-2034 (USD Million)
- 6.4. Retail Pharmacies
- 6.4.1. Global Refractory Gout Market, by Retail Pharmacies, by Region, 2020-2034 (USD Million)
- 6.5. Online Pharmacies
- 6.5.1. Global Refractory Gout Market, by Online Pharmacies, by Region, 2020-2034 (USD Million)
7. Global Refractory Gout Market, by Geography
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Refractory Gout Market Assessment, By Geography, 2020-2034 (USD Million)
- 7.3. Refractory Gout Market - North America
- 7.3.1. North America: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.3.2. North America: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.3.3. Refractory Gout Market - US
- 7.3.3.1. US: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.3.3.2. US: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.3.4. Refractory Gout Market - Canada
- 7.3.4.1. Canada: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.3.4.2. Canada: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.4. Refractory Gout Market - Europe
- 7.4.1. Europe: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.4.2. Europe: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.4.3. Refractory Gout Market - UK
- 7.4.3.1. UK: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.4.3.2. UK: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.4.4. Refractory Gout Market - France
- 7.4.4.1. France: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.4.4.2. France: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.4.5. Refractory Gout Market - Germany
- 7.4.5.1. Germany: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.4.5.2. Germany: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.4.6. Refractory Gout Market - Italy
- 7.4.6.1. Italy: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.4.6.2. Italy: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.4.7. Refractory Gout Market - Spain
- 7.4.7.1. Spain: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.4.7.2. Spain: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.4.8. Refractory Gout Market - Netherlands
- 7.4.8.1. Netherlands: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.4.8.2. Netherlands: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.4.9. Refractory Gout Market - Russia
- 7.4.9.1. Russia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.4.9.2. Russia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.4.10. Refractory Gout Market - Rest of Europe
- 7.4.10.1. Rest of Europe: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.4.10.2. Rest of Europe: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.5. Refractory Gout Market - Asia Pacific
- 7.5.1. Asia Pacific: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.5.2. Asia Pacific: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.5.3. Refractory Gout Market - China
- 7.5.3.1. China: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.5.3.2. China: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.5.4. Refractory Gout Market - India
- 7.5.4.1. India: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.5.4.2. India: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.5.5. Refractory Gout Market - Malaysia
- 7.5.5.1. Malaysia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.5.5.2. Malaysia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.5.6. Refractory Gout Market - Japan
- 7.5.6.1. Japan: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.5.6.2. Japan: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.5.7. Refractory Gout Market - Indonesia
- 7.5.7.1. Indonesia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.5.7.2. Indonesia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.5.8. Refractory Gout Market - South Korea
- 7.5.8.1. South Korea: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.5.8.2. South Korea: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.5.9. Refractory Gout Market - Australia
- 7.5.9.1. Australia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.5.9.2. Australia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.5.10. Refractory Gout Market - Rest of Asia Pacific
- 7.5.10.1. Rest of Asia Pacific: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.5.10.2. Rest of Asia Pacific: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.6. Refractory Gout Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.6.2. Middle East & Africa: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.6.3. Refractory Gout Market - Saudi Arabia
- 7.6.3.1. Saudi Arabia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.6.3.2. Saudi Arabia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.6.4. Refractory Gout Market - UAE
- 7.6.4.1. UAE: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.6.4.2. UAE: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.6.5. Refractory Gout Market - Israel
- 7.6.5.1. Israel: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.6.5.2. Israel: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.6.6. Refractory Gout Market - South Africa
- 7.6.6.1. South Africa: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.6.6.2. South Africa: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.6.7. Refractory Gout Market - Rest of Middle East & Africa
- 7.6.7.1. Rest of Middle East & Africa: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.6.7.2. Rest of Middle East & Africa: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.7. Refractory Gout Market - Latin America
- 7.7.1. Latin America: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.7.2. Latin America: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.7.3. Refractory Gout Market - Mexico
- 7.7.3.1. Mexico: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.7.3.2. Mexico: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.7.4. Refractory Gout Market - Brazil
- 7.7.4.1. Brazil: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.7.4.2. Brazil: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.7.5. Refractory Gout Market - Argentina
- 7.7.5.1. Argentina: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.7.5.2. Argentina: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.7.6. Refractory Gout Market - Rest of Latin America
- 7.7.6.1. Rest of Latin America: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
- 7.7.6.2. Rest of Latin America: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
- 9.1. Horizon Therapeutics
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
- 9.2. Novartis AG
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
- 9.3. Takeda Pharmaceuticals
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
- 9.4. Grifols, S.A.
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
- 9.5. Ironwood Pharmaceuticals
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
- 9.6. Selecta Biosciences
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
- 9.7. Teijin Pharma
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
- 9.8. Pfizer Inc.
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
- 9.9. Sobi (Swedish Orphan Biovitrum)
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
- 9.10. LG Chem
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
- 9.11. AstraZeneca
- 9.11.1. Company Overview
- 9.11.2. Financial Performance
- 9.11.3. Product Benchmarking
- 9.11.4. Recent Development
- 9.12. Mylan N.V.
- 9.12.1. Company Overview
- 9.12.2. Financial Performance
- 9.12.3. Product Benchmarking
- 9.12.4. Recent Development
- 9.13. Sanofi
- 9.13.1. Company Overview
- 9.13.2. Financial Performance
- 9.13.3. Product Benchmarking
- 9.13.4. Recent Development
- 9.14. GlaxoSmithKline plc (GSK)
- 9.14.1. Company Overview
- 9.14.2. Financial Performance
- 9.14.3. Product Benchmarking
- 9.14.4. Recent Development
- 9.15. Ardea Biosciences
- 9.15.1. Company Overview
- 9.15.2. Financial Performance
- 9.15.3. Product Benchmarking
- 9.15.4. Recent Development
